Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma

Cancer. 1986 Jul 1;58(1):18-21. doi: 10.1002/1097-0142(19860701)58:1<18::aid-cncr2820580105>;2-c.


Twenty-one patients with malignant mesothelioma were treated with an experimental intracavitary chemotherapy regimen of weekly intraperitoneal or intrapleural cisplatin (90-100 mg/m2) with simultaneous intravenous sodium thiosulfate delivered to protect against cisplatin-induced nephrotoxicity. One of eight patients (12.5%) receiving intrapleural therapy and nine of 13 patients receiving intraperitoneal therapy demonstrated objective evidence of a clinical response, including three surgically defined major tumor regressions (23%). Patients receiving intrapleural treatment had more advanced disease prior to therapy than those receiving intraperitoneal therapy. It was concluded that intraperitoneal cisplatin is an active treatment program for intra-abdominally localized mesothelioma. Additional investigation of intrapleural cisplatin should be undertaken in a patient population with less advanced disease or following surgical debulking.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Actuarial Analysis
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Catheters, Indwelling
  • Cisplatin / administration & dosage
  • Cisplatin / adverse effects
  • Cisplatin / therapeutic use*
  • Female
  • Humans
  • Injections, Intraperitoneal
  • Male
  • Mesothelioma / drug therapy*
  • Mesothelioma / mortality
  • Middle Aged
  • Nausea / prevention & control
  • Pleura
  • Punctures
  • Thiosulfates / administration & dosage


  • Thiosulfates
  • sodium thiosulfate
  • Cisplatin